In 2022, he became CEO of RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the United States. As CEO, Stephen is focused on ensuring RLS continues to meet the needs of its customers and other stakeholders, while charting a new path for the company that leads to sustainable, long-term growth and success.

Previously, Stephen served as CEO and Chair of the Board of Perma-Fix Medical, an industry leader addressing the global shortage of Tc-99m in nuclear medicine. He was also a Founder, Principal, and Vice President at Triad Isotopes—now part of Jubilant Radiopharma, the second-largest radiopharmaceutical network in the United States. At Triad, he helped secure over $300 million in growth opportunities. Over his career, he has also served as a board member or advisor to multiple companies across the medical sector.

Prior to joining RLS (USA) Inc., Mr. Lucas held positions as Chief Financial Officer of Pharmalogic Holdings, Inc and Triad Isotopes, Inc. where he spent nearly 15 years in nuclear medicine finance and accounting.  During that time, he facilitated multiple rounds of debt financing and restructuring, participated in multiple acquisitions, and built finance and accounting functions of newly-formed companies.

Mr. Lucas graduated from the University of Central Florida where he earned a master’s degree in accounting.  He is a certified public accountant, and a member of the American Institute of Certified Public Accountants (AICPA).

In 2022, he became COO of RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the United States. As COO, Trey leads day-to-day operations of the RLS network, while driving organizational alignment, operations strategy, and performance management for all RLS employees.

Bankson joined RLS after most recently serving as an executive healthcare consultant. Previously, he held senior operations roles at a wide range of pharmacies, including major radiopharmacies like Triad Isotopes—now part of Jubilant Radiopharma, the second-largest radiopharmaceutical network in the United States. He holds a BS in Pharmacy from Auburn University and an MS in Healthcare Administration from the University of Alabama at Birmingham.

Renee Wolf is a dynamic and accomplished HR leader with a passion for building high-performance teams and driving organizational success.  With over 25 years of experience in the field, Renee brings a wealth of expertise in strategic HR management, talent acquisition, employee development and employee engagement.

Renee joined RLS after most recently serving as Vice President, Human Resources for Drake Capital Solutions.  Prior to Drake Capital, Renee spent 17 years with Akorn Pharmaceuticals and held the position of Vice President, Human Resources.  She also held various leadership roles with CNA Financial and Netcom, Inc.

Renee holds a B.S. in Psychology from DePaul University, Chicago.

Janet Otts-Watson is a seasoned executive with a proven track record in sales and marketing leadership roles within the pharmaceutical and biotech industries.  With extensive experience and a deep understanding of the unique dynamics of this specialized field, Janet plays a pivotal role in driving revenue growth and market expansion for RLS.  With over 25 years of experience in the healthcare sector, Janet has established herself as a results-oriented leader.  Her strategic mindset, coupled with her comprehensive knowledge of the radiopharmaceutical market, enables her to develop and execute effective sales and marketing strategies that drive commercial success.

Prior to joining RLS, Janet held senior leadership positions at leading healthcare companies including Jazz Pharmaceuticals, PLC, EUSA Pharma, Bristol Myers Squibb, Glaxo-Smith Kline/Corixa and Sanofi-Synthelabo Pharmaceuticals where she built high-performing sales teams, established strategic partnerships, and expanded market share.  Her expertise spans a wide range of areas, including product positioning, market research, brand management, and customer relationship development.

Janet holds a BS in Business Administration, Cum Laude from University of Alabama and an MBA in Business Administration from Samford University.

Molchan is responsible for setting national, regional and local business development strategy across the RLS network. In addition, he is charged with building and maintaining strategic partnerships between RLS and other industry-leading radiopharmacy firms.

Prior to joining RLS, Molchan served as President and CEO of Digirad, a leading medical device manufacturer and healthcare service provider. He also served as Chief Financial Officer (CFO) at Ultrascan, a mobile ultrasound service business. Molchan holds a B.S. in Economics from the United States Air Force Academy and an MBA from the University of Southern California.